Sepragen.com

Home | Contact Us 


Online Catalog


View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at sales@sepragen.com.



How Can We Help You?
Click here to contact us!

 



Sepragen Corporation Announces New Distributors For Its BioTech Business In Europe

HAYWARD, CA, February 15, 2000 - Sepragen Corporation (OTC BB: SPGNU, SPGNA, SPGNW) today announced the signing of three new distributors for its biotech separations products in Europe.

The new distributors are Analis S.A. for Belgium, Proteigene S. A. for France and Switzerland, and KronLab GmbH for the German speaking countries (Germany, Austria and Switzerland). Sepragen’s larger European based customers include Aventis, Baxter International, Glaxo Wellcome, Serono and Smith-Kline Beecham.

Vinit Saxena, Chairman and CEO of Sepragen commented, “Our products are increasingly being used in the isolation and manufacture of ‘new generation’ biological drugs being brought to the market,” he continued “This increased support will provide our customers greater security in committing long-term resources towards adopting our unique technology for their production needs.”

Sepragen Corporation develops and markets technology along with equipment and supplies for process chromatography applications. Sepragen has developed a number of patented applications that provide large market opportunities in the food and beverage industry, including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as well as extracting proteins from whey. The company holds over 14 issued patents relating to its core technology.

Return to News Archives main page



The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.


Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2018 Sepragen Corporation. All rights reserved. (510) 475-0650